[go: up one dir, main page]

PE20090625A1 - Composicion farmaceutica que contiene buprenorfina y nalmefeno - Google Patents

Composicion farmaceutica que contiene buprenorfina y nalmefeno

Info

Publication number
PE20090625A1
PE20090625A1 PE2008000411A PE2008000411A PE20090625A1 PE 20090625 A1 PE20090625 A1 PE 20090625A1 PE 2008000411 A PE2008000411 A PE 2008000411A PE 2008000411 A PE2008000411 A PE 2008000411A PE 20090625 A1 PE20090625 A1 PE 20090625A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
composition containing
nalmefene
buprenorphine
containing buprenorphine
Prior art date
Application number
PE2008000411A
Other languages
English (en)
Inventor
Christopher Bourne Chapleo
Neil Hyde
Original Assignee
Reckitt Benckiser Healthcare
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reckitt Benckiser Healthcare filed Critical Reckitt Benckiser Healthcare
Publication of PE20090625A1 publication Critical patent/PE20090625A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION ANALGESICA QUE CONTIENE: A) BUPRENORFINA QUE SE ENCUENTRA EN UNA CANTIDAD DE 10uG a 8MG; Y B) NALMEFENO, TAL QUE LA RELACION EN PESO DE BUPRENORFINA A NALMEFENO SE ENCUENTRA EN EL RANGO ENTRE 22,6:1 Y 40:1. SE REFIERE TAMBIEN A UN METODO DE TRATAMIENTO PARA EL DOLOR. DICHA COMPOSICION FARMACEUTICA SE PRESENTA EN UNA FORMA DE DOSIFICACION PARENTERAL UNITARIA O EN UNA FORMA DE DOSIFICACION UNITARIA ADECUADA PARA UNA ADMINISTRACION POR LA MUCOSA O LA DERMIS
PE2008000411A 2007-03-01 2008-02-29 Composicion farmaceutica que contiene buprenorfina y nalmefeno PE20090625A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0703933A GB2447013A (en) 2007-03-01 2007-03-01 Analgesic composition containing buprenorphone and nalmefene

Publications (1)

Publication Number Publication Date
PE20090625A1 true PE20090625A1 (es) 2009-06-04

Family

ID=37965707

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2012000471A PE20120956A1 (es) 2007-03-01 2008-02-29 Composicion farmaceutica que contiene buprenorfina y nalmefeno
PE2008000411A PE20090625A1 (es) 2007-03-01 2008-02-29 Composicion farmaceutica que contiene buprenorfina y nalmefeno

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2012000471A PE20120956A1 (es) 2007-03-01 2008-02-29 Composicion farmaceutica que contiene buprenorfina y nalmefeno

Country Status (21)

Country Link
US (1) US8497280B2 (es)
EP (1) EP2114452B1 (es)
JP (1) JP5577102B2 (es)
KR (1) KR101437461B1 (es)
CN (1) CN101622012B (es)
AR (1) AR065582A1 (es)
AU (1) AU2008220572B2 (es)
BR (1) BRPI0807903A2 (es)
CA (1) CA2678568C (es)
CL (1) CL2008000607A1 (es)
DK (1) DK2114452T3 (es)
ES (1) ES2476865T3 (es)
GB (1) GB2447013A (es)
HR (1) HRP20140591T1 (es)
MX (1) MX2009009134A (es)
PE (2) PE20120956A1 (es)
PL (1) PL2114452T3 (es)
PT (1) PT2114452E (es)
TW (1) TWI468163B (es)
WO (1) WO2008104736A1 (es)
ZA (1) ZA200905692B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
HRP20160110T1 (hr) * 2009-05-25 2016-03-11 H. Lundbeck A/S Priprema nalmefen hidroklorida iz naltreksona
CN110101702A (zh) 2012-04-17 2019-08-09 普渡制药公司 用于治疗阿片样物质所致不良药效学响应的系统和方法
CN103637983B (zh) * 2013-12-16 2017-08-04 科贝源(北京)生物医药科技有限公司 一种含有盐酸纳美芬的药物组合物及其制备方法
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CN104922061B (zh) * 2015-05-26 2017-09-22 成都天台山制药有限公司 盐酸纳美芬注射液药物组合物和制法
AU2018291397A1 (en) 2017-06-30 2020-01-16 Purdue Pharma L.P. Method of treatment and dosage forms thereof
CA3091443A1 (en) * 2018-02-22 2019-08-29 Avior, Inc. Transmucosal film composition and methods of making and using the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8728294D0 (en) * 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5272149A (en) * 1992-05-05 1993-12-21 Stalling Reginald W Symptom controlled receptor substitution for addiction withdrawl
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
AU755790B2 (en) * 1997-12-22 2002-12-19 Euro-Celtique S.A. A method of preventing abuse of opioid dosage forms
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
US20050191340A1 (en) * 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine
US9539303B2 (en) * 2006-04-24 2017-01-10 Celgene Corporation Treatment of Ras-expressing tumors
US8957027B2 (en) * 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
US20110015168A1 (en) * 2007-01-19 2011-01-20 Mitchell Keegan Methods for increasing levels of human fetal hemoglobin

Also Published As

Publication number Publication date
JP2010520184A (ja) 2010-06-10
KR20090115862A (ko) 2009-11-09
CN101622012B (zh) 2012-05-30
US20100152222A1 (en) 2010-06-17
PE20120956A1 (es) 2012-08-01
GB2447013A (en) 2008-09-03
DK2114452T3 (da) 2014-06-30
PT2114452E (pt) 2014-07-15
MX2009009134A (es) 2009-09-03
CL2008000607A1 (es) 2008-10-03
HK1139868A1 (en) 2010-09-30
US8497280B2 (en) 2013-07-30
WO2008104736A1 (en) 2008-09-04
CN101622012A (zh) 2010-01-06
HRP20140591T1 (hr) 2014-09-12
AU2008220572B2 (en) 2014-03-27
ZA200905692B (en) 2010-10-27
JP5577102B2 (ja) 2014-08-20
KR101437461B1 (ko) 2014-09-05
PL2114452T3 (pl) 2014-09-30
GB0703933D0 (en) 2007-04-11
TWI468163B (zh) 2015-01-11
ES2476865T3 (es) 2014-07-15
CA2678568A1 (en) 2008-09-04
CA2678568C (en) 2015-06-16
EP2114452B1 (en) 2014-04-09
TW200900067A (en) 2009-01-01
BRPI0807903A2 (pt) 2014-06-17
EP2114452A1 (en) 2009-11-11
AR065582A1 (es) 2009-06-17
AU2008220572A1 (en) 2008-09-04

Similar Documents

Publication Publication Date Title
PE20081799A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
PE20090168A1 (es) Composiciones farmaceuticas de buprenorfina y naloxona
PE20090625A1 (es) Composicion farmaceutica que contiene buprenorfina y nalmefeno
AR065581A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
DE602007007991D1 (de) Kleinvolumige, orale, transmukosale dosierungsformen mit sufentanil zur schmerzbehandlung
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
CL2012000313A1 (es) Composición de dosificación de película que comprende una matriz portadora, entre 2-16 mg de buprenorfina, entre 0,5-5 mg de naloxona y un tampón que proporciona un ph local entre 2-4; procedimiento de preparación; uso en el tratamiento de la dependencia de narcóticos en un usuario.
MX2007004736A (es) Composicion farmaceutica que comprende diclofenaco.
FI3782612T3 (fi) Sytidiinianalogien oraalisia formulaatioita ja menetelmiä niiden käyttämiseksi
PE20190391A1 (es) Formas de dosificacion del tapentadol novedosas y potentes
AR031682A1 (es) Composiciones farmaceuticas
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
EP1781277A4 (en) COMBINATION PREPARATION
MXPA06013133A (es) Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina.
GT200800235A (es) Formulacion de medicamento liquida
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis
PA8789101A1 (es) Composición farmacéutica estable que comprende una sal de vinflunina hidrosoluble
AR048958A1 (es) Medicamento en forma de pelicula para administracion por via oral, que contiene estriol
AR061046A1 (es) Mirtazapina para el tratamiento del dolor neuropatico
CL2008002485A1 (es) Uso de gestagenos en combinacion con (6s)-5-metiltetrahidrofolato para el tratamiento de la endometriosis con reduccion de los efectos colaterales terapeuticos; procedimiento de preparacion de una composicion farmaceutica que comprende a dichos compuestos.
ES2436344B1 (es) Composición farmacéutica de diacetilmorfina y naloxona para administración oral
GR1007337B (el) Αναβραζουσα φαρμακευτικη συνθεση που περιεχει παρακεταμολη και ορφεναδρινη
GT201300318A (es) Composición farmacéutica para uso en inflamación y dolor

Legal Events

Date Code Title Description
FC Refusal